Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Tax Provisions (2021 - 2026)

Aytu Biopharma has reported Tax Provisions over the past 6 years, most recently at $437000.0 for Q2 2025.

  • Quarterly Tax Provisions fell 48.1% to $437000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $315000.0 through Dec 2025, down 78.79% year-over-year, with the annual reading at $437000.0 for FY2025, 79.6% down from the prior year.
  • Tax Provisions was $437000.0 for Q2 2025 at Aytu Biopharma, up from -$122000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $842000.0 in Q2 2024 and troughed at -$283000.0 in Q4 2024.
  • The 5-year median for Tax Provisions is $126000.0 (2023), against an average of $248454.5.
  • The largest YoY upside for Tax Provisions was 568.25% in 2024 against a maximum downside of 135.37% in 2024.
  • A 5-year view of Tax Provisions shows it stood at -$3000.0 in 2021, then skyrocketed by 4000.0% to $117000.0 in 2022, then surged by 583.76% to $800000.0 in 2023, then tumbled by 135.38% to -$283000.0 in 2024, then surged by 254.42% to $437000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Tax Provisions are $437000.0 (Q2 2025), -$122000.0 (Q1 2025), and -$283000.0 (Q4 2024).